je.st
news
Tag: gilead
Q1 2016 EPS Estimates for Gilead Sciences, Inc. (GILD) Lifted by Leerink Partner
2016-04-14 04:02:18| Biotech - Topix.net
Gilead Sciences, Inc. - Analysts at Leerink Partner lifted their Q1 2016 earnings per share estimates for Gilead Sciences in a note issued to investors on Thursday, according to Zacks Investment Research . Leerink Partner analyst G. Porges now expects that the brokerage will earn $3.29 per share for the quarter, up from their prior forecast of $3.08.
Tags: partner
sciences
estimates
eps
Gilead Sciences, Inc. (GILD) Rating Reiterated by Mizuho
2016-04-10 23:14:22| Biotech - Topix.net
's stock had its "buy" rating reaffirmed by investment analysts at Mizuho in a research report issued on Sunday, Marketbeat.com reports. They presently have a $130.00 target price on the biopharmaceutical company's stock.
Tags: rating
sciences
gilead
mizuho
Foster City's Gilead seeks six-story lab: New expansion proposed for biotech's corporate campus
2016-04-07 17:23:53| Biotech - Topix.net
The multi-billion dollar success of the Foster City-headquartered Gilead Sciences is propelling the biopharmaceutical giant to continue expanding into its nearly 72-acre corporate campus, including a proposed new laboratory officials say could help the company save lives. The city's Planning Commission will meet Thursday, April 7, for a study session to review the proposal to demolish an existing single-story building and construct a six-story lab and office building that will bring it closer to fully building out the 2.5 million square feet of space to which Gilead holds entitlements.
Tags: corporate
proposed
expansion
campus
Gilead paying up to $1.2B for Nimbus unit, drug candidate
2016-04-04 22:15:41| Biotech - Topix.net
Biologic drugmaker Gilead Sciences Inc. said Monday that it will buy a subsidiary of Nimbus Therapeutics LLC and its experimental pill for an increasingly common metabolic disorder that causes life-threatening fat buildup in the liver. Gilead, based in Foster City, California, will pay $400 million for Nimbus Apollo Inc. Parent company Nimbus Therapeutics, based in Cambridge, Massachusetts, could receive another $800 million if Nimbus Apollo's drug development program meets certain milestones in testing results and medicine approval and sales.
Tags: unit
drug
candidate
paying
Gilead Sciences, Inc. (GILD) Downgraded by Vetr Inc. to "Buy"
2016-04-04 08:36:27| Biotech - Topix.net
They presently have a $104.96 target price on the biopharmaceutical company's stock. Vetr 's target price would suggest a potential upside of 11.52% from the stock's current price.
Tags: to
buy
sciences
downgraded